1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson
Apr 04, 2019•1 hr
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer".
BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X
Rivaroxaban: doi.org/10.1056/NEJMoa1814630
Apixaban: doi.org/10.1056/NEJMoa1814468
Back us on Patreon! www.patreon.com/plenarysession
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast